PharmaSource Podcast

“The market for lipid nanoparticles really exploded during COVID-19,” says Alexander Aust, LNP manufacturing expert.

Alexander Aust, a consultant specialising in lipid nanoparticle (LNP) manufacturin…

The COVID-19 pandemic didn't just disrupt pharmaceutical manufacturing—it catalysed a fundamental shift in how we approach CDMO partnerships. Johnson & Johnson's Paolo Giudici reveals how their four-…

Leadership insights from our latest Women in BioPharma meetup.

"I fully expect that the industry will have multiple female CEOs in the years to come," predicts Elizabeth Hickman, Chief Executive Offi…

Gene editing and cell therapy, they’re going to be entrenched modalities, much like small molecules and antibodies are today, that will fundamentally reshape healthcare.” says Devyn Smith.

Devyn Smi…

Stephen Sheehan of Alkermes shares their new governance framework for high-performing CDMO partnerships.

As Director of External Development & Manufacturing at Alkermes, Stephen Sheehan brings over a…

For us, it’s not a transaction. It really is a partnership,” says Nikki Whitfield, CEO of Upperton Pharma Solutions.

Nikki Whitfield brings over three decades of pharmaceutical development experience…

Hanns-Christian Mahler, Chief Enablement Officer at ten23 health, is redefining leadership in pharmaceutical manufacturing: “I believe collaboration at the workplace should be primarily based on trus…

John Childers, Director of Business Development for Wacker Biotech’s North American operations, emphasises the importance of early CDMO partnerships: “Working with an experienced CDMO partner can re…

The pharmaceutical industry faces a significant challenge with patent expiries threatening established revenue streams of approximately $300 Billion USD.

Major brands are approaching patent expiry cr…

David Caron, Senior Vice-President of CMC, AL102 at Immunome, shares why choosing the right CDMO partner can make or break a biotech’s development timeline: “For biotechs, the main business challenge…

Dr. Avencia Sánchez-Mejías is CEO and co-founder of Integra Therapeutics, a Barcelona-based biotech company developing next-generation gene-editing tools. With a background in molecular biology and c…

"The reality is, we have a lot of CDMOs don't they really know what they're getting into" says Herman Bozenhardt

Herman Bozenhardt, a pharmaceutical manufacturing consultant with decades of experien…

GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2029.

However, their rapid rise raises important questions about resou…

“Treat them as a partner, not just a supplier. It’s a mindset you need to get into.” – Federica Fraschetti, MSD

Federica Fraschetti, Associate Director of External Manufacturing at MSD, brings years …

“Sustainability is no longer just a buzzword in the pharmaceutical industry. It’s a critical business imperative,” says Hywel Woolf, Global Sustainability Manager at Sharp Services. “

“We’re seeing i…

“Manufacturing network strategy is about connecting the dots and seeing the interconnectivity between different brands,” explains Daniel Hurni, Director of Manufacturing Network Strategy and Business…

Live from CPHI Milan 2024, this episode is a roundup of conversations with a number of key exhibitors Recipharm, Tjoapack, Renaissance Lakewood, Ecolab and NovaCina.

As you'll hear, it was a noisy ev…

"As Americans, we are very unaware of the value proposition of Poland," says Marty Henehan, highlighting the untapped potential of Central European biopharmaceutical manufacturing for North American …

Joerg Ahlgrimm brings over two decades of experience in pharmaceutical manufacturing and operations to his role as Chief Executive Officer at SK pharmteco.

His distinguished career includes leadersh…

"In underserved markets, there's always a challenge of reaching patients due to political and economic pressures. Through smart packaging, logistics, and distribution, we're committed to providing he…